The cardiovascular effect of the uremic solute indole-3 acetic acid

Journal of the American Society of Nephrology

Volumn 26, Issue 4, 2015, Pages 876-887

  Dou, Laetitia ^a   Sallée, Marion ^a,b   Cerini, Claire ^a   Poitevin, Stéphane ^a   Gondouin, Bertrand ^a,b   Jourde Chiche, Noemie ^b   Fallague, Karim ^a   Brunet, Philippe ^a,b   Calaf, Raymond ^a   Dussol, Bertrand ^a,b   Mallet, Bernard ^c   Dignat George, Françoise ^a   Burtey, Stephane ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL DE LA CONCEPTION   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; AROMATIC HYDROCARBON RECEPTOR; C REACTIVE PROTEIN; CHOLESTEROL; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDICAN; INDOLEACETIC ACID; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PARA CRESYL SULFATE; PHOSPHATE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; UREMIC TOXIN; INDOLEACETIC ACID DERIVATIVE; PTGS2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SMOKING; SOLUTE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UPREGULATION; UREMIA; BLOOD; CARDIOVASCULAR DISEASES; CHRONIC KIDNEY FAILURE; COMPLICATION; METABOLISM; MIDDLE AGED; MORTALITY; UMBILICAL VEIN ENDOTHELIAL CELL; VASCULAR ENDOTHELIUM; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2; ENDOTHELIUM, VASCULAR; FEMALE; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INDOLEACETIC ACIDS; MALE; MIDDLE AGED; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION; UREMIA; YOUNG ADULT;

EID: 84926443402     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2013121283     Document Type: Article

References (44)

1. Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J: Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 111, Suppl(Suppl): S4-S9, 2008
2. Raff AC, Meyer TW, Hostetter TH: New insights into uremic toxicity. Curr Opin Nephrol Hypertens 17: 560-565, 2008
3. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, Argiles A; European Uremic Toxin Work Group: Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 23: 1258-1270, 2012
4. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Brunet P: Vascular incompetence in dialysis patients - protein-bound uremic toxins and endothelial dysfunction. Semin Dial 24: 327-337, 2011
5. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat-George F, Brunet P: The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 5: 1302-1308, 2007
6. Glorieux G, Cohen G, Jankowski J, Vanholder R: Platelet/leukocyte activation, inflammation, and uremia. Semin Dial 22: 423-427, 2009
7. Jourde-Chiche N, Dou L, Cerini C, Dignat-George F, Vanholder R, Brunet P: Protein-bound toxins - update 2009. Semin Dial 22: 334-339, 2009
8. Vanholder R, De Smet R, Glorieux G, Argilés A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jörres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W; European Uremic Toxin Work Group (EUTox): Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 63: 1934-1943, 2003
9. Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, Calaf R, Lacroix R, Jourde-Chiche N, Poitevin S, Arnaud L, Vanholder R, Brunet P, Dignat-George F, Burtey S: Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney Int 84: 733-744, 2013
10. Heath-Pagliuso S, Rogers WJ, Tullis K, Seidel SD, Cenijn PH, Brouwer A, Denison MS: Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry 37: 11508-11515, 1998
11. Haarmann-Stemmann T, Bothe H, Abel J: Growth factors, cytokines and their receptors as downstream targets of arylhydrocarbon receptor (AhR) signaling pathways. Biochem Pharmacol 77: 508-520, 2009
12. Kopf PG, Walker MK: 2,3,7,8-tetrachlorodibenzo-p-dioxin increases reactive oxygen species production in human endothelial cells via induction of cytochrome P4501A1. Toxicol Appl Pharmacol 245: 91-99, 2010
13. Wu D, Nishimura N, Kuo V, Fiehn O, Shahbaz S, Van Winkle L, Matsumura F, Vogel CF: Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol 31: 1260-1267, 2011
14. Korashy HM, El-Kadi AO: The role of aryl hydrocarbon receptor in the pathogenesis of cardiovascular diseases. Drug Metab Rev 38: 411-450, 2006
15. Cipollone F, Cicolini G, Bucci M: Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectives. Pharmacol Ther 118: 161-180, 2008
16. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin Work Group (EUTox): Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4: 1551-1558, 2009
17. Liabeuf S, Glorieux G, Lenglet A, Diouf M, Schepers E, Desjardins L, Choukroun G, Vanholder R, Massy ZA; European Uremic Toxin (EUTox) Work Group: Does p-cresylglucuronide have the same impact on mortality as other protein-bound uremic toxins? PLoS ONE 8: e67168, 2013
18. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, Temmar M, Choukroun G, Vanholder R, Massy ZA; European Uraemic Toxin Work Group (EUTox): Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25: 1183-1191, 2010
19. Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, Tsai CJ, Wu MS: Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients - a prospective cohort study. Nephrol Dial Transplant 27: 1169-1175, 2012
20. Eloot S, Van Biesen W, Glorieux G, Neirynck N, Dhondt A, Vanholder R: Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients? PLoS ONE 8: e76838, 2013
21. Watanabe H, Miyamoto Y, Otagiri M, Maruyama T: Update on the pharmacokinetics and redox properties of protein-bound uremic toxins. J Pharm Sci 100: 3682-3695, 2011
22. De Smet R, Dhondt A, Eloot S, Galli F, Waterloos MA, Vanholder R: Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant 22: 2006-2012, 2007
23. Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M: Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 25: 2672-2679, 2010
24. Eloot S, Schepers E, Barreto DV, Barreto FC, Liabeuf S, Van Biesen W, Verbeke F, Glorieux G, Choukroun G, Massy Z, Vanholder R: Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol 6: 1266-1273, 2011
25. Dalton TP, Puga A, Shertzer HG: Induction of cellular oxidative stress by aryl hydrocarbon receptor activation. Chem Biol Interact 141: 77-95, 2002
26. Degner SC, Kemp MQ, Hockings JK, Romagnolo DF: Cyclooxygenase-2 promoter activation by the aromatic hydrocarbon receptor in breast cancer mcf-7 cells: Repressive effects of conjugated linoleic acid. Nutr Cancer 59: 248-257, 2007
27. Félétou M, Huang Y, Vanhoutte PM: Endothelium-mediated control of vascular tone: COX-1 and COX-2 products. Br J Pharmacol 164: 894-912, 2011
28. Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, Iezzi A, Ucchino S, Boccoli G, Saba V, Chiarelli F, Cuccurullo F, Mezzetti A: Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation 104: 921-927, 2001
29. Beloqui O, Páramo JA, Orbe J, Benito A, Colina I, Monasterio A, Díez J: Monocyte cyclooxygenase-2 overactivity: A new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors? Eur Heart J 26: 153-158, 2005
30. Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, Marnett LJ, Morrow JD, Fazio S, Linton MF: Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105: 1816-1823, 2002
31. Bai Y, Sigala W, Adams GR, Vaziri ND: Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol 29: 213-221, 2009
32. Vaziri ND, Bai Y, Yuan J, Said HL, Sigala W, Ni Z: ApoA-1 mimetic peptide reverses uremia-induced upregulation of pro-atherogenic pathways in the aorta. Am J Nephrol 32: 201-211, 2010
33. van der Giet M, Tölle M, Pratico D, Lufft V, Schuchardt M, Hörl MP, Zidek W, Tietge UJ: Increased type IIA secretory phospholipase A(2) expression contributes to oxidative stress in end-stage renal disease. J Mol Med (Berl) 88: 75-83, 2010
34. Caballo C, Palomo M, Cases A, Galán AM, Molina P, Vera M, Bosch X, Escolar G, Diaz-Ricart M: NFκB in the development of endothelial activation and damage in uremia: An in vitro approach. PLoS ONE 7: e43374, 2012
35. Lin CC, Hsieh HL, Shih RH, Chi PL, Cheng SE, Yang CM: Up-regulation of COX-2/PGE2 by endothelin-1 via MAPK-dependent NF-κB pathway in mouse brain microvascular endothelial cells. Cell Commun Signal 11: 8, 2013
36. Hsieh HL, Lin CC, Chan HJ, Yang CM, Yang CM: c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells. J Neuroinflammation 9: 152, 2012
37. Dong B, Nishimura N, Vogel CF, Tohyama C, Matsumura F: TCDD-induced cyclooxygenase-2 expression is mediated by the nongenomic pathway in mouse MMDD1 macula densa cells and kidneys. Biochem Pharmacol 79: 487-497, 2010
38. Li W, Vogel CF, Wu D, Matsumura F: Non-genomic action of TCDD to induce inflammatory responses in HepG2 human hepatoma cells and in liver of C57BL/6J mice. Biol Chem 391: 1205-1219, 2010
39. Tardieu D, Jaeg JP, Deloly A, Corpet DE, Cadet J, Petit CR: The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21: 973-976, 2000
40. Sugiyama T, Yoshimoto T, Sato R, Fukai N, Ozawa N, Shichiri M, Hirata Y: Endothelin-1 induces cyclooxygenase-2 expression and generation of reactive oxygen species in endothelial cells. J Cardiovasc Pharmacol 44[Suppl 1]: S332-S335, 2004
41. Zhang DX, Gutterman DD: Mitochondrial reactive oxygen species-mediated signaling in endothelial cells. Am J Physiol Heart Circ Physiol 292: H2023-H2031, 2007
42. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T: Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 63: 1671-1680, 2003
43. Calaf R, Cerini C, Génovésio C, Verhaeghe P, Jourde-Chiche N, Bergé-Lefranc D, Gondouin B, Dou L, Morange S, Argilés A, Rathelot P, Dignat-George F, Brunet P, Charpiot P: Determination of uremic solutes in biological fluids of chronic kidney disease patients by HPLC assay. J Chromatogr B Analyt Technol Biomed Life Sci 879: 2281-2286, 2011
44. Jaffe EA, Nachman RL, Becker CG, Minick CR: Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 52: 2745-2756, 1973